Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

295 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Acute myocardial infarction as a systemic prothrombotic condition evidenced by increased von Willebrand factor protein over ADAMTS13 activity in coronary and systemic circulation.
Horii M, Uemura S, Uemura M, Matsumoto M, Ishizashi H, Imagawa K, Iwama H, Takeda Y, Kawata H, Nakajima T, Fujimura Y, Saito Y. Horii M, et al. Among authors: iwama h. Heart Vessels. 2008 Sep;23(5):301-7. doi: 10.1007/s00380-008-1053-x. Epub 2008 Sep 20. Heart Vessels. 2008. PMID: 18810578
Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction.
Iwama H, Uemura S, Naya N, Imagawa K, Takemoto Y, Asai O, Onoue K, Okayama S, Somekawa S, Kida Y, Takeda Y, Nakatani K, Takaoka M, Kawata H, Horii M, Nakajima T, Doi N, Saito Y. Iwama H, et al. J Am Coll Cardiol. 2006 Apr 18;47(8):1559-67. doi: 10.1016/j.jacc.2005.11.064. Epub 2006 Mar 27. J Am Coll Cardiol. 2006. PMID: 16630991 Free article.
Treatment with recombinant placental growth factor (PlGF) enhances both angiogenesis and arteriogenesis and improves survival after myocardial infarction.
Takeda Y, Uemura S, Iwama H, Imagawa K, Nishida T, Onoue K, Takemoto Y, Soeda T, Okayama S, Somekawa S, Ishigami K, Takaoka M, Kawata H, Kubo A, Horii M, Nakajima T, Saito Y. Takeda Y, et al. Among authors: iwama h. Circ J. 2009 Sep;73(9):1674-82. doi: 10.1253/circj.cj-08-1067. Epub 2009 Jul 15. Circ J. 2009. PMID: 19602778 Free article.
Usefulness of soluble Fms-like tyrosine kinase-1 as a biomarker of acute severe heart failure in patients with acute myocardial infarction.
Onoue K, Uemura S, Takeda Y, Somekawa S, Iwama H, Nishida T, Morikawa Y, Nakagawa H, Tsutsumi T, Sung JH, Takemoto Y, Soeda T, Okayama S, Ishigami K, Kawata H, Horii M, Nakajima T, Saito Y. Onoue K, et al. Among authors: iwama h. Am J Cardiol. 2009 Dec 1;104(11):1478-83. doi: 10.1016/j.amjcard.2009.07.016. Am J Cardiol. 2009. PMID: 19932778
Reduction of circulating soluble fms-like tyrosine kinase-1 plays a significant role in renal dysfunction-associated aggravation of atherosclerosis.
Onoue K, Uemura S, Takeda Y, Somekawa S, Iwama H, Imagawa K, Nishida T, Morikawa Y, Takemoto Y, Asai O, Soeda T, Okayama S, Ishigami K, Nakatani K, Kawata H, Horii M, Nakajima T, Akai Y, Iwano M, Saito Y. Onoue K, et al. Among authors: iwama h. Circulation. 2009 Dec 15;120(24):2470-7. doi: 10.1161/CIRCULATIONAHA.109.867929. Circulation. 2009. PMID: 19948974
Proteinuria and Reduced Estimated Glomerular Filtration Rate Are Independent Risk Factors for Contrast-Induced Nephropathy After Cardiac Catheterization.
Saito Y, Watanabe M, Aonuma K, Hirayama A, Tamaki N, Tsutsui H, Murohara T, Ogawa H, Akasaka T, Yoshimura M, Sato A, Takayama T, Sakakibara M, Suzuki S, Ishigami K, Onoue K; CINC-J study investigators. Saito Y, et al. Circ J. 2015;79(7):1624-30. doi: 10.1253/circj.CJ-14-1345. Epub 2015 Apr 17. Circ J. 2015. PMID: 25891891 Free article. Clinical Trial.
295 results